(Q64074228)

2

0 references

Longlong Bao

3

0 references

Xiaoyan Zhou

4

0 references

Zhe Wang

5

0 references

Peizhen Hu

6

0 references

Nengtai Ouyang

7

0 references

Xiaojuan Li

8

0 references

Yi Shi

9

0 references

Gang Chen

10

0 references

Peiyi Xia

11

0 references

Meiying Chui

12

0 references

Wencai Li

13

0 references

Ying Jia

14

0 references

Yueping Liu

15

0 references

Junjun Liu

16

0 references

Junyi Ye

17

0 references

Zhe Zhang

18

0 references

Hong Bu

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

19

0 references

language of work or name

English

0 references

publication date

April 2019

0 references

published in

Cancer Science

0 references

volume

110

0 references

issue

4

0 references

page(s)

1389-1400

0 references

cites work

1 reference

12 December 2020

Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.

1 reference

12 December 2020

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

12 December 2020

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

1 reference

12 December 2020

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

1 reference

12 December 2020

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

12 December 2020

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

12 December 2020

Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line

1 reference

12 December 2020

Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance

1 reference

12 December 2020

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

1 reference

12 December 2020

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

12 December 2020

FOXA1 Expression in Breast Cancer Correlation with Luminal Subtype A and Survival

1 reference

12 December 2020

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

12 December 2020

Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.

1 reference

12 December 2020

Targeting the RAF-MEK-ERK pathway in cancer therapy

1 reference

12 December 2020

Induction of Akt activity by chemotherapy confers acquired resistance

1 reference

12 December 2020

Genomic grade index is associated with response to chemotherapy in patients with breast cancer

1 reference

12 December 2020

High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer

1 reference

12 December 2020

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

1 reference

12 December 2020

FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer

1 reference

12 December 2020

ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer

1 reference

12 December 2020

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

1 reference

12 December 2020

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.

1 reference

12 December 2020

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer

1 reference

12 December 2020

Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines

1 reference

12 December 2020

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

1 reference

12 December 2020

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

12 December 2020

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

12 December 2020

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

1 reference

12 December 2020

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

12 December 2020

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

12 December 2020

Comprehensive molecular portraits of human breast tumours

1 reference

12 December 2020

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility

1 reference

12 December 2020

Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.

1 reference

12 December 2020

Mutational landscape and significance across 12 major cancer types

1 reference

12 December 2020

Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

1 reference

12 December 2020

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

12 December 2020

Cyclin D1 gene amplification is highly homogeneous in breast cancer

1 reference

12 December 2020

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

1 reference

12 December 2020

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel

1 reference

12 December 2020

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

1 reference

12 December 2020

Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

1 reference

12 December 2020

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay

1 reference

12 December 2020

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

1 reference

12 December 2020

p53 as an Effector or Inhibitor of Therapy Response

1 reference

12 December 2020

Hereditary truncating mutations of DNA repair and other genes inBRCA1/BRCA2/PALB2-negatively tested breast cancer patients

1 reference

12 December 2020

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

1 reference

12 December 2020

BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report

1 reference

12 December 2020

A microscopic landscape of the invasive breast cancer genome

1 reference

12 December 2020

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

1 reference

12 December 2020

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation

1 reference

12 December 2020